News Column

ONCONOVA THERAPEUTICS, INC. FILES (8-K) Disclosing Regulation FD Disclosure

July 10, 2014

Item 7.01. Regulation FD Disclosure.

Onconova Therapeutics, Inc. (the "Company") intends to file a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (the "Commission") during the third quarter of 2014 to register the offer and sale from time to time of any combination of common stock, preferred stock, debt securities, warrants or units, in one or more offerings. The registration statement is intended to give the Company future flexibility to take advantage of financing opportunities when market conditions are favorable.

The registration statement on Form S-3 has not yet been filed with the Commission. The securities may not be sold and offers to buy may not be accepted prior to the time such registration statement becomes effective. This current report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

The information in this Current Report on Form 8-K is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.



For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters